|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZSCAN21 |
Gene summary for ZSCAN21 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZSCAN21 | Gene ID | 7589 |
| Gene name | zinc finger and SCAN domain containing 21 | |
| Gene Alias | NY-REN-21 | |
| Cytomap | 7q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9Y5A6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7589 | ZSCAN21 | HCC1_Meng | Human | Liver | HCC | 6.47e-11 | 3.01e-02 | 0.0246 |
| 7589 | ZSCAN21 | S014 | Human | Liver | HCC | 1.10e-08 | 3.46e-01 | 0.2254 |
| 7589 | ZSCAN21 | S015 | Human | Liver | HCC | 1.90e-06 | 3.13e-01 | 0.2375 |
| 7589 | ZSCAN21 | S016 | Human | Liver | HCC | 6.29e-09 | 3.11e-01 | 0.2243 |
| 7589 | ZSCAN21 | S027 | Human | Liver | HCC | 3.53e-06 | 6.24e-01 | 0.2446 |
| 7589 | ZSCAN21 | S028 | Human | Liver | HCC | 1.20e-24 | 9.68e-01 | 0.2503 |
| 7589 | ZSCAN21 | S029 | Human | Liver | HCC | 8.49e-22 | 9.56e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0048285 | Liver | HCC | organelle fission | 254/7958 | 488/18723 | 1.07e-05 | 1.23e-04 | 254 |
| GO:0000280 | Liver | HCC | nuclear division | 220/7958 | 439/18723 | 6.90e-04 | 4.25e-03 | 220 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZSCAN21 | SNV | Missense_Mutation | c.262N>G | p.Leu88Val | p.L88V | Q9Y5A6 | protein_coding | deleterious(0.04) | possibly_damaging(0.558) | TCGA-A2-A0YJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD | |
| ZSCAN21 | SNV | Missense_Mutation | c.571N>G | p.Gln191Glu | p.Q191E | Q9Y5A6 | protein_coding | tolerated(0.78) | benign(0.007) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZSCAN21 | SNV | Missense_Mutation | novel | c.583A>C | p.Lys195Gln | p.K195Q | Q9Y5A6 | protein_coding | tolerated(0.56) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZSCAN21 | SNV | Missense_Mutation | rs780220822 | c.1174G>A | p.Glu392Lys | p.E392K | Q9Y5A6 | protein_coding | deleterious(0.02) | possibly_damaging(0.595) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZSCAN21 | SNV | Missense_Mutation | c.212G>A | p.Cys71Tyr | p.C71Y | Q9Y5A6 | protein_coding | tolerated(1) | probably_damaging(0.967) | TCGA-BH-A0EB-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| ZSCAN21 | SNV | Missense_Mutation | novel | c.510N>G | p.His170Gln | p.H170Q | Q9Y5A6 | protein_coding | tolerated(0.31) | benign(0.013) | TCGA-HN-A2NL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| ZSCAN21 | insertion | Nonsense_Mutation | novel | c.1135_1136insTTGGATGCTGATTTACTTGTATCTATGCGCTATC | p.Tyr379PhefsTer4 | p.Y379Ffs*4 | Q9Y5A6 | protein_coding | TCGA-A2-A0EX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ZSCAN21 | insertion | Nonsense_Mutation | novel | c.1353_1354insGTCTCAAAATAAATAAATAAAATAAATATTTTTTT | p.Thr452ValfsTer4 | p.T452Vfs*4 | Q9Y5A6 | protein_coding | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| ZSCAN21 | SNV | Missense_Mutation | novel | c.423G>C | p.Gln141His | p.Q141H | Q9Y5A6 | protein_coding | tolerated(0.09) | benign(0.003) | TCGA-C5-A1BJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ZSCAN21 | SNV | Missense_Mutation | novel | c.652G>C | p.Glu218Gln | p.E218Q | Q9Y5A6 | protein_coding | tolerated(0.33) | benign(0.019) | TCGA-C5-A1BJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |